Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells

Oral Oncology

Volumn 40, Issue 7, 2004, Pages 713-719

  Harada, Koji ^a   Kawaguchi, Shin Ichi ^a   Supriatno, ^a   Onoue, Tomitaro ^a   Yoshida, Hideo ^a   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Chemoradiation; Oral cancer; Radiation; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROPYRIMIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ADHESION; CELL COUNT; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MALE; MOUSE; MOUTH CANCER; MULTIMODALITY CANCER THERAPY; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASM TRANSPLANTATION; OXONIC ACID; PYRIDINES; TEGAFUR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 2542506412     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2004.01.013     Document Type: Article

References (20)

1. Nakajima Y., Miyamoto T., Tanabe M., Watanabe I., Terasima T. Enhancement of mammalian cell killing by 5-fluorouracil in combination with X-rays. Cancer Res. 39(9):1979;3763-3767
2. Smalley S.R., Kimler B.F., Evans R.G. 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys. 20(2):1991;207-211
3. Balart J., Capella G., de los Inocentes R.M., de Andres J., Ares C., Craven-Bartle J., et al. Treatment with 5-fluorouracil enhances radiosensitivity of the human pancreatic cancer cell line MiaPaCa-2. Pancreatology. 2(1):2002;40-45
4. Shirasaka T., Shimamato Y., Ohshimo H., Yamaguchi M., Kato T., Yonekura K., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7(5):1996;548-557
5. Fukushima M., Satake H., Uchida J., Shimamoto Y., Kato T., Takechi T., et al. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 13(4):1998;693-698
6. Fukushima M., Shimamoto Y., Kato T., Uchida J., Yonekura R., Ohshimo H., et al. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs. 9(9):1998;817-823
7. Sakata Y., Ohtsu A., Horikoshi N., Sugimachi K., Mitachi Y., Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 34(11):1998;1715-1720
8. Kawahara M., Furuse K., Segawa Y., Yoshimori K., Matsui K., Kudoh S., et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 85(7):2001;939-943
9. Cohen S.J., Leichman C.G., Yeslow G., Beard M., Proefrock A., Roedig B., et al. Phase I and pharmacokinetic study of once daily oral administration of S-1in patients with advanced cancer. Clin Cancer Res. 8(7):2002;2116-2122
10. Inuyama Y., Kida A., Tsukuda M., Kohno N., Satake B. Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho. 28(10):2001;1381-1390. Japanese, abstract in English
11. Kip. 1 induces growth arrest and apoptosis in an oral cancer cell line Oral Oncol. 38:2002;730-736
12. Shirasuna K., Sato M., Miyazaki T. A neoplastic epithelial duct cell line established from an irradiated human salivary gland. Cancer (Phila.). 48:1981;745-752
13. Shirasuna K., Kurokawa R., Sato M., Morioka S., Miyazaki T. Isolation and characterization of different clones including myoepithelial-like variants from a clonal neoplastic epithelial duct cell line of human salivary gland origin. Cancer Res. 46:1986;1418-1426
14. Johnson R.R. Elementary statistics. 1980;Duxbury Press, Massachusetts
15. Steel G.G., Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 5(1):1979;85-91
16. Berry R.J. Effects of some metabolic inhibitors on X-ray dose-response curves for the survival of mammalian cells in vitro, and on early recovery between fractionated X-ray doses. Br J Radiol. 39(462):1966;458-463
17. Lo T.C., Wiley A.L. Jr., Ansfield F.J., Brandenburg J.H., Davis H.L. Jr., Gollin F.F., et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am J Roentgenol. 126(2):1976;229-235
18. Matsubara S. Fundamental remarks on combination radiotherapy with anti-neoplastic agents. Jpn J Cancer Clin. 45(4):1999;271-273. Japanese, abstract in English
19. Vogelzang N.J. Continuous infusion chemotherapy: a critical review. J Clin Oncol. 2(11):1984;1289-1304
20. Shirasaka T., Shimamoto Y., Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 53(17):1993;4004-4009